Suven gets patents in S Africa and China for neurology NCEs
This article was originally published in Scrip
Executive Summary
Suven Life Sciences has been granted patents in South Africa and China for two new chemical entities (NCE) for the treatment of neurodegenerative diseases. These patents are valid until 2024 and 2025 respectively.